The patents cover sales of Biogen products for MS that are covered by a Forward Pharma patent and have dimethyl fumarate as an active pharmaceutical ingredient. The two companies say they intend ...

On today's stock market, Biogen stock popped 4.6% to 201.99. "Some encouraging signs of life for the launch products," he said in a client note. "While the base business continues to compress and ...

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA ...

It's commonplace for brands to work with influencers to amplify a campaign. The reality is that these human media channels are paid guns-for-hire and consumers are more sceptical than ever with ...

Amid declining demand for MS drugs and Spinraza, Biogen believes its new products, Leqembi for Alzheimer ... You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

In outside U.S. markets, Biogen records product sales (excluding Japan, Taiwan, and South Korea where Shionogi holds the rights) and pays royalties to Sage Therapeutics. Zurzuvae has not yet been ...

Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases ...

Tecfidera was for years Biogen’s flagship product, accounting for about one-third of the company’s revenue as recently as 2020. The expiry of key patents and entry of lower-cost generic rivals in the ...